Sean E. Aeder

Array ( [id] => 13447173 [patent_doc_number] => 20180275129 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-27 [patent_title] => Reagents and Methods for Breast Cancer Detection [patent_app_type] => utility [patent_app_number] => 16/002493 [patent_app_country] => US [patent_app_date] => 2018-06-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11195 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 121 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16002493 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15713291 [patent_doc_number] => 20200103411 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-02 [patent_title] => Predicting Cancer Treatment Outcome With T-DM1 [patent_app_type] => utility [patent_app_number] => 16/617580 [patent_app_country] => US [patent_app_date] => 2018-06-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3987 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 101 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16617580 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17785769 [patent_doc_number] => 11408887 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-08-09 [patent_title] => Biomarkers for diagnosis of lung cancer [patent_app_type] => utility [patent_app_number] => 16/615147 [patent_app_country] => US [patent_app_date] => 2018-05-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 19 [patent_no_of_words] => 22743 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 238 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16615147 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13410401 [patent_doc_number] => 20180256743 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-13 [patent_title] => NEW TUMOR MARKER FOR THE RHABDOMYOSARCOMA [patent_app_type] => utility [patent_app_number] => 15/982416 [patent_app_country] => US [patent_app_date] => 2018-05-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4583 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 142 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15982416 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16312384 [patent_doc_number] => 20200291122 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-17 [patent_title] => TREATMENT OF CANCER WITH ANTI-GITR AGONIST ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/612956 [patent_app_country] => US [patent_app_date] => 2018-05-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35556 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16612956 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15771421 [patent_doc_number] => 20200116728 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-16 [patent_title] => METHODS FOR DIAGNOSING HIGH-RISK CANCER USING POLYSIALIC ACID AND ONE OR MORE TISSUE-SPECIFIC BIOMARKERS [patent_app_type] => utility [patent_app_number] => 16/611596 [patent_app_country] => US [patent_app_date] => 2018-05-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25204 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -179 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16611596 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13374729 [patent_doc_number] => 20180238906 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-23 [patent_title] => METHOD FOR EVALUATING THE POSSIBILITY OF SUFFERING FROM PANCREATIC DISEASE [patent_app_type] => utility [patent_app_number] => 15/961012 [patent_app_country] => US [patent_app_date] => 2018-04-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4844 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 95 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15961012 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17770446 [patent_doc_number] => 11402381 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-08-02 [patent_title] => Methods of identifying an individual to be treated by chemotherapy based on cytokeratin-19 fragments (CYFRA 21-1) and carcinoembryonic antigen (CEA) marker molecules and related uses [patent_app_type] => utility [patent_app_number] => 15/952731 [patent_app_country] => US [patent_app_date] => 2018-04-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 6 [patent_no_of_words] => 9774 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 201 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15952731 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13354711 [patent_doc_number] => 20180228895 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-16 [patent_title] => Subcutaneous anti-HER2 Antibody Formulations and Uses Thereof [patent_app_type] => utility [patent_app_number] => 15/949616 [patent_app_country] => US [patent_app_date] => 2018-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22298 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15949616 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13461779 [patent_doc_number] => 20180282432 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-04 [patent_title] => HETERODIMERIC ANTIBODIES THAT BIND CD3 AND TUMOR ANTIGENS [patent_app_type] => utility [patent_app_number] => 15/945679 [patent_app_country] => US [patent_app_date] => 2018-04-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25160 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15945679 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13342921 [patent_doc_number] => 20180223000 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-09 [patent_title] => HETERODIMERIC ANTIBODIES THAT BIND CD3 AND TUMOR ANTIGENS [patent_app_type] => utility [patent_app_number] => 15/945681 [patent_app_country] => US [patent_app_date] => 2018-04-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28462 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15945681 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13794033 [patent_doc_number] => 20190010555 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-10 [patent_title] => SYNTHETIC LETHALITY AND THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 15/943068 [patent_app_country] => US [patent_app_date] => 2018-04-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28228 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 113 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15943068 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16916291 [patent_doc_number] => 20210189383 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-24 [patent_title] => METHOD FOR EVALUATING MULTIPLE DIFFERENT GENES OF INTEREST [patent_app_type] => utility [patent_app_number] => 16/498618 [patent_app_country] => US [patent_app_date] => 2018-03-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22570 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16498618 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13462559 [patent_doc_number] => 20180282822 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-04 [patent_title] => METHODS FOR SELECTING TREATMENT REGIMENS AND PREDICTING OUTCOMES IN CANCER PATIENTS [patent_app_type] => utility [patent_app_number] => 15/938888 [patent_app_country] => US [patent_app_date] => 2018-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38817 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15938888 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15646829 [patent_doc_number] => 20200085944 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-19 [patent_title] => RNA VACCINE AND IMMUNE CHECKPOINT INHIBITORS FOR COMBINED ANTICANCER THERAPY [patent_app_type] => utility [patent_app_number] => 16/494422 [patent_app_country] => US [patent_app_date] => 2018-03-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 64200 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16494422 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18428971 [patent_doc_number] => 11674182 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-06-13 [patent_title] => Biomarker for HER2-positive cancer and anti-HER2 therapy and applications thereof [patent_app_type] => utility [patent_app_number] => 16/491993 [patent_app_country] => US [patent_app_date] => 2018-03-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 35 [patent_no_of_words] => 19886 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 152 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16491993 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16999481 [patent_doc_number] => 11078272 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-03 [patent_title] => Treatment of pediatric brain tumors with targeting of CD47 pathway [patent_app_type] => utility [patent_app_number] => 15/912447 [patent_app_country] => US [patent_app_date] => 2018-03-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 153 [patent_no_of_words] => 20498 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15912447 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14043491 [patent_doc_number] => 20190077852 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-14 [patent_title] => ANTI-EMP2 THERAPY REDUCES CANCER STEM CELLS [patent_app_type] => utility [patent_app_number] => 15/908269 [patent_app_country] => US [patent_app_date] => 2018-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18351 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15908269 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13898759 [patent_doc_number] => 20190038584 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-07 [patent_title] => CARCINOMA DIAGNOSIS AND TREATMENT, BASED ON ODC1 GENOTYPE [patent_app_type] => utility [patent_app_number] => 15/904153 [patent_app_country] => US [patent_app_date] => 2018-02-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22463 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15904153 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13400619 [patent_doc_number] => 20180251852 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-06 [patent_title] => MUTANT CALRETICULIN FOR THE DIAGNOSIS OF MYELOID MALIGNANCIES [patent_app_type] => utility [patent_app_number] => 15/902859 [patent_app_country] => US [patent_app_date] => 2018-02-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 99984 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15902859 [rel_patent_id] =>[rel_patent_doc_number] =>)